The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence
Open accessAbstract
CONTEXT: Atherosclerotic vascular disease is an enormous public health problem. A number of emerging risk factors for atherosclerosis have recently been proposed to help identify high-risk individuals. OBJECTIVE: To review the epidemiological, basic science, and clinical trial evidence concerning 4 emerging risk factors: C-reactive protein, lipoprotein(a), fibrinogen, and homocysteine. DATA SOURCES: Using the terms atherosclerosis, cardiovascular disease, risk factors, prevention, screening, C-reactive protein, lipoprotein(a), fibrinogen, and homocysteine, we searched the MEDLINE database from January 1990 to January 2003. Conference proceedings, abstract booklets, bibliographies of pertinent articles and books, and personal files were hand searched to identify additional articles. STUDY SELECTION: Original investigations and reviews of the epidemiology of atherosclerosis and the association of conventional and novel risk factors with vascular risk were selected. On the basis of the search strategy, 373 relevant studies were identified. DATA EXTRACTION: A diverse array of studies were examined, including randomized controlled trials, prospective cohort studies, systematic overviews, case-control, cross-sectional, and mechanistic studies. Data extraction was performed by one of the authors. DATA SYNTHESIS: The available epidemiological and basic science evidence supports, to varying degrees, independent associations between these 4 candidate risk factors and atherosclerotic vascular disease. However, there is relatively little data regarding the additive yield of screening for these factors over that of validated global risk assessment strategies currently in use. Furthermore, controlled intervention studies targeting individuals with these factors for proven risk-reduction therapies, or specifically treating these factors with available therapies, are few. The explanatory power of the major, established cardiovascular risk factors has been systematically underestimated. CONCLUSIONS: Although C-reactive protein, lipoprotein(a), fibrinogen, and homocysteine are associated with vascular disease risk, their optimal use in routine screening and risk stratification remains to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401 · cited 2×
“should be targeted for aggressive treatment irrespective of CRP level.(11)”
BackgroundFrosst, P., Blom, H. J., Milos, R., Goyette, P., Sheppard, C. A., Matthews, R. G., Boers, G. J. H., den Heijer, M., Kluijtmans, L. A. J., van den Heuve, L. P., et al. (1995) · Nature Genetics · doi:10.1038/ng0595-111 · Cited by 5,653
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
Mortality by cause for eight regions of the world: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07493-4 · Cited by 4,043 · cited 1×
“world’s leading cause of death and disability.(2) Atherosclerotic vascular disease (ASVD), which encompasses coro-”
Background(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
Epstein, F. H., Fuster, V., Badimon, L., Badimon, J. J., & Chesebro, J. H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201303260506 · Cited by 3,725
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Yusuf, S., Reddy, S., Ôunpuu, S., & Anand, S. (2001) · Circulation · doi:10.1161/hc4601.099487 · Cited by 2,972
Self-citationRidker, P. M., Buring, J. E., Cook, N. R., & Rifai, N. (2003) · Circulation · doi:10.1161/01.cir.0000055014.62083.05 · Cited by 2,292
D'Agostino, R. B., Grundy, S., Sullivan, L. M., Wilson, P., & for the CHD Risk Prediction Group (2001) · JAMA · doi:10.1001/jama.286.2.180 · Cited by 2,108
Homocysteine and Risk of Ischemic Heart Disease and Stroke: A Meta-analysis
Homocysteine Studies Collaboration (2002) · JAMA · doi:10.1001/jama.288.16.2015 · Cited by 2,059
Danesh, J., Collins, R., Appleby, P., & Peto, R. (1998) · JAMA · doi:10.1001/jama.279.18.1477 · Cited by 2,026
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis
Wald, D. S., Law, M., & Morris, J. K. (2002) · BMJ · doi:10.1136/bmj.325.7374.1202 · Cited by 1,946
Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells
Pasceri, V., Willerson, J. T., & Yeh, E. T. H. (2000) · Circulation · doi:10.1161/01.cir.102.18.2165 · Cited by 1,940
Pearson, T. A., Blair, S. N., Daniels, S. R., Eckel, R. H., Fair, J. M., Fortmann, S. P., Franklin, B. A., Goldstein, L. B., Greenland, P., Grundy, S. M., et al. (2002) · Circulation · doi:10.1161/01.cir.0000020190.45892.75 · Cited by 1,854
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
Danesh, J. (2000) · BMJ · doi:10.1136/bmj.321.7255.199 · Cited by 1,692
Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-5-786_2 · Cited by 1,418
Ridker, P. M. (2001) · Circulation · doi:10.1161/01.cir.103.13.1813 · Cited by 1,402
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Ridker, P. M., Stampfer, M. J., & Rifai, N. (2001) · JAMA · doi:10.1001/jama.285.19.2481 · Cited by 1,296
Pepys, M. B., & Baltz, M. L. (1983) · Advances in Immunology · doi:10.1016/s0065-2776(08)60379-x · Cited by 1,272
The natural history of homocystinuria due to cystathionine beta-synthase deficiency.
Mudd, S. H., Skovby, F., Levy, H. L., Pettigrew, K. D., Wilcken, B. M., Pyeritz, R. E., Andria, G., Boers, G. H. J., Bromberg, I. L., & Cerone, R. (1985) · PubMed · Cited by 1,256
Yusuf, S., Reddy, S., Ôunpuu, S., & Anand, S. (2001) · Circulation · doi:10.1161/hc4701.099488 · Cited by 1,141
Self-citationLowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials
Collaboration, H. L. T. (1998) · BMJ · doi:10.1136/bmj.316.7135.894 · Cited by 1,084
Plasma Concentration of C-Reactive Protein and Risk of Developing Peripheral Vascular Disease
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.97.5.425 · Cited by 975
Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies
Danesh, J., Collins, R., & Peto, R. (2000) · Circulation · doi:10.1161/01.cir.102.10.1082 · Cited by 938
MTHFR 677C→T Polymorphism and Risk of Coronary Heart Disease: A Meta-analysis
Klerk, M., Verhoef, P., Clarke, R., Blom, H. J., Kok, F. J., Schouten, E. G., & and the MTHFR Studies Collaboration Group (2002) · JAMA · doi:10.1001/jama.288.16.2023 · Cited by 934
Clarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M., & Peto, R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010013 · Cited by 877
Zwaka, T. P., Hombach, V., & Torzewski, J. (2001) · Circulation · doi:10.1161/01.cir.103.9.1194 · Cited by 845
Freeman, D. J., Norrie, J., Caslake, M. J., Gaw, A., Ford, I., Lowe, G. D. O., O’Reilly, D. S. J., Packard, C. J., Sattar, N., & for the West of Scotland Coronary Prevention Study Group (2002) · Diabetes · doi:10.2337/diabetes.51.5.1596 · Cited by 728
Stamler, J., Stamler, R., Neaton, J. D., Wentworth, D., Daviglus, M. L., Garside, D., Dyer, A. R., Liu, K., & Greenland, P. (1999) · JAMA · doi:10.1001/jama.282.21.2012 · Cited by 725
Werstuck, G. H., Lentz, S. R., Dayal, S., Hossain, G. S., Sood, S. K., Shi, Y. Y., Zhou, J., Maeda, N., Krisans, S. K., Malinow, M. R., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11596 · Cited by 702
Verma, S., Li, S.-H., Badiwala, M. V., Weisel, R. D., Fedak, P. W. M., Li, R.-K., Dhillon, B., & Mickle, D. A. G. (2002) · Circulation · doi:10.1161/01.cir.0000015126.83143.b4 · Cited by 634
Biasucci, L. M., Liuzzo, G., Grillo, R. L., Caligiuri, G., Rebuzzi, A. G., Buffon, A., Summaria, F., Ginnetti, F., Fadda, G., & Maseri, A. (1999) · Circulation · doi:10.1161/01.cir.99.7.855 · Cited by 582
Torzewski, M., Rist, C., Mortensen, R. F., Zwaka, T. P., Bienek, M., Waltenberger, J., Koenig, W., Schmitz, G., Hombach, V., & Torzewski, J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.9.2094 · Cited by 581
Torzewski, J., Torzewski, M., Bowyer, D. E., Fröhlich, M., Koenig, W., Waltenberger, J., Fitzsimmons, C., & Hombach, V. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.9.1386 · Cited by 561
The Relation of Markers of Inflammation to the Development of Glucose Disorders in the Elderly
Barzilay, J. I., Abraham, L., Heckbert, S. R., Cushman, M., Kuller, L. H., Resnick, H. E., & Tracy, R. P. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2384 · Cited by 545
Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine Levels
Schnyder, G., Roffi, M., Pin, R., Flammer, Y., Lange, H., Eberli, F. R., Meier, B., Turi, Z. G., & Hess, O. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011364 · Cited by 532
Alfthan, G., Pekkanen, J., Jauhiainen, M., Pitkäniemi, J., Karvonen, M., Tuomilehto, J., Salonen, J. T., & Ehnholm, C. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90078-7 · Cited by 527
A Prospective Study of Lipoprotein(a) and the Risk of Myocardial Infarction
Ridker, P. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510180065035 · Cited by 512
CARLSON, L. A., HAMSTEN, A., & ASPLUND, A. (1989) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1989.tb01393.x · Cited by 443 · cited 1×
“Lipoprotein(a) concentrations are unaffected by most available lipid-lowering therapies, with the exception of high-dose nicotinic acid, which is often poorly tolerated.(70) This has made it difficult to demonstrate that Lp(a) plays a direct role in vascular disease, since large-scale controlled intervention studies e…”
BackgroundMeade, T. W., Imeson, J., & Stirling, Y. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92556-6 · Cited by 426
Coronary in-stent restenosis: Current status and future strategies
Lowe, H. C., Oesterle, S. N., & Khachigian, L. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01742-9 · Cited by 414
Heeschen, C., Hamm, C. W., Bruemmer, J., & Simoons, M. L. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00581-7 · Cited by 414
Prospective Study of Markers of Hemostatic Function With Risk of Ischemic Stroke
Folsom, A. R., Rosamond, W. D., Shahar, E., Cooper, L. S., Aleksic, N., Nieto, F. J., Rasmussen, M. L., & Wu, K. K. (1999) · Circulation · doi:10.1161/01.cir.100.7.736 · Cited by 407
Schnyder, G., Roffi, M., Flammer, Y., Pin, R., & Hess, O. M. (2002) · JAMA · doi:10.1001/jama.288.8.973 · Cited by 379
Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice
Grainger, D. J., Kemp, P. R., Liu, A. C., Lawn, R. M., & Metcalfe, J. C. (1994) · Nature · doi:10.1038/370460a0 · Cited by 352
C-Reactive Protein and Outcome After Ischemic Stroke
Muir, K. W., Weir, C. J., Alwan, W., Squire, I. B., & Lees, K. R. (1999) · Stroke · doi:10.1161/01.str.30.5.981 · Cited by 317
Prognostic Influence of Increased C-Reactive Protein and Fibrinogen Levels in Ischemic Stroke
Di Napoli, M., Papa, F., & Bocola, V. (2001) · Stroke · doi:10.1161/01.str.32.1.133 · Cited by 315
Marcovina, S. M., Albers, J. J., Scanu, A. M., Kennedy, H., Giaculli, F., Berg, K., Couderc, R., Dati, F., Rifai, N., Sakurabayashi, I., et al. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.12.1956 · Cited by 313
Measuring Plasma Fibrinogen to Predict Stroke and Myocardial Infarction: An Update
Maresca, G., Di Blasio, A., Marchioli, R., & Di Minno, G. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.6.1368 · Cited by 306
Law, M. R., Wald, N. J., Wu, T., Hackshaw, A., & Bailey, A. (1994) · BMJ · doi:10.1136/bmj.308.6925.363 · Cited by 305
Blood Levels of Homocysteine and Increased Risks of Cardiovascular Disease: Causal or Casual?
Christen, W. G., Ajani, U. A., Glynn, R. J., & Hennekens, C. H. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.422 · Cited by 304
Lipoprotein(a). A unique risk factor for atherothrombotic disease.
Loscalzo, J. (1990) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.10.5.672 · Cited by 296
De Bree, A., Verschuren, W. M. M., Kromhout, D., Kluijtmans, L. A. J., & Blom, H. J. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.599 · Cited by 282
Smith, S. C., Jr. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/edxm-hp68 · Cited by 281
Magnus, P., & Beaglehole, R. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.22.2657 · Cited by 277
Chew, D. P., Bhatt, D. L., Robbins, M. A., Penn, M. S., Schneider, J. P., Lauer, M. S., Topol, E. J., & Ellis, S. G. (2001) · Circulation · doi:10.1161/hc3401.095074 · Cited by 260
Homocysteine and cardiovascular disease:
Mangoni, A. A., & Jackson, S. H. D. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01021-5 · Cited by 242
Apolipoprotein(a) Kringle IV Repeat Number Predicts Risk for Coronary Heart Disease
Kraft, H. G., Lingenhel, A., Köchl, S., Hoppichler, F., Kronenberg, F., Abe, A., Mühlberger, V., Schönitzer, D., & Utermann, G. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.6.713 · Cited by 231
Ford, E. S., Smith, S. J., Stroup, D. F., Steinberg, K. K., Mueller, P. W., & Thacker, S. B. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.59 · Cited by 230
Folsom, A. R., Aleksic, N., Catellier, D., Juneja, H. S., & Wu, K. K. (2002) · American Heart Journal · doi:10.1067/mhj.2002.124054 · Cited by 227
Park, R., Detrano, R., Xiang, M., Fu, P., Ibrahim, Y., LaBree, L., & Azen, S. (2002) · Circulation · doi:10.1161/01.cir.0000033819.29662.09 · Cited by 224
Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation
Walter, D. H., Fichtlscherer, S., Sellwig, M., Auch-Schwelk, W., Schächinger, V., & Zeiher, A. M. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01193-1 · Cited by 222
Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: Results of a meta-analysis
Fallon, U. B., & Ben-Shlomo, Y. (2003) · Neurology · doi:10.1212/wnl.60.3.526 · Cited by 221
Zebrack, J. S., Muhlestein, J. B., Horne, B. D., & Anderson, J. L. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01804-6 · Cited by 219
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial
Meade, T., Zuhrie, R., Cook, C., & Cooper, J. (2002) · BMJ · doi:10.1136/bmj.325.7373.1139 · Cited by 208
Zebrack, J. S., Anderson, J. L., Maycock, C. A., Horne, B. D., Bair, T. L., & Muhlestein, J. B. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02190-7 · Cited by 195
Moons, K. G. M., van Es, G.-A., Deckers, J. W., Habbema, J. D. F., & Grobbee, D. E. (1997) · Epidemiology · doi:10.1097/00001648-199701000-00002 · Cited by 189 · cited 1×
“ing to prevalence or spectrum of severity of disease in a given population.(120) It is therefore critical that promising”
Backgroundvon Eckardstein, A., Schulte, H., Cullen, P., & Assmann, G. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01126-8 · Cited by 187
Collaboration, H. L. T. (1998) · PubMed Central · Cited by 181
Beaglehole, R., & Magnus, P. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.6.1117 · Cited by 169
Ridker, P. M., Buring, J. E., Cook, N. R., & Rifai, N. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00157-0 · Cited by 165
Measuring plasma fibrinogen to predict stroke and myocardial infarction.
Di Minno, G., & Mancini, M. (1990) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.10.1.1 · Cited by 162
Inflammation and Stroke: The Leiden 85-Plus Study
van Exel, E., Gussekloo, J., de Craen, A. J. M., Bootsma-van der Wiel, A., Frölich, M., & Westendorp, R. G. J. (2002) · Stroke · doi:10.1161/01.str.0000014206.05597.9e · Cited by 162
C-Reactive Protein — To Screen or Not to Screen?
Mosca, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejme020127 · Cited by 156
Need to Test the Arterial Inflammation Hypothesis
Bhatt, D. L., & Topol, E. J. (2002) · Circulation · doi:10.1161/01.cir.0000021112.29409.a2 · Cited by 150
(2002) · Cerebrovascular Diseases · doi:10.1159/000047761 · Cited by 149
Total plasma homocysteine level and risk of cardiovascular disease
Bautista, L. E., Arenas, I. A., Peñuela, A., & Martínez, L. X. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00434-1 · Cited by 148
Guijarro, C. (2001) · Circulation · doi:10.1161/circ.104.22.e127 · Cited by 141
Regulation of acute phase gene expression by inflammatory mediators.
Gh, F., & Fuller, G. M. (1987) · PubMed · Cited by 138
Gaw, A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117263 · Cited by 137
Apolipoprotein(a) Induces Monocyte Chemotactic Activity in Human Vascular Endothelial Cells
Poon, M., Zhang, X., Dunsky, K. G., Taubman, M. B., & Harpel, P. C. (1997) · Circulation · doi:10.1161/01.cir.96.8.2514 · Cited by 131
Vitamin Intervention for Stroke Prevention (VISP) Trial: Rationale and Design
Spence, J. D., Howard, V. J., Chambless, L. E., Malinow, M. R., Pettigrew, L. C., Stampfer, M. J., & Toole, J. F. (2001) · Neuroepidemiology · doi:10.1159/000054753 · Cited by 125
Lipoprotein (a) and stroke: Table 1
Milionis, H. J., WINDER, A. F., & Mikhailidis, D. P. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.7.487 · Cited by 122
A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women
Manson, J. E., Gaziano, J. M., Spelsberg, A., Ridker, P. M., Cook, N. R., Buring, J. E., Willett, W. C., & Hennekens, C. H. (1995) · Annals of Epidemiology · doi:10.1016/1047-2797(94)00091-7 · Cited by 119
Walter, D. H., Fichtlscherer, S., Britten, M. B., Rosin, P., Auch–Schwelk, W., Schächinger, V., & Zeiher, A. M. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01662-x · Cited by 118
Pillarisetti, S., Paka, L., Obunike, J. C., Berglund, L., & Goldberg, I. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119602 · Cited by 112
Kluijtmans, L. A. J., Boers, G. H. J., Kraus, J. P., van den Heuvel, L. P. W. J., Cruysberg, J. R. M., Trijbels, F. J. M., & Blom, H. J. (1999) · The American Journal of Human Genetics · doi:10.1086/302439 · Cited by 109
Milazzo, D., Biasucci, L. M., Luciani, N., Martinelli, L., Canosa, C., Schiavello, R., Maseri, A., & Possati, G. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00333-1 · Cited by 106
Yap, S., Naughten, E. R., Wilcken, B. M., Wilcken, D. E. L., & Boers, G. H. J. (2000) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2000-8100 · Cited by 105
Tommasi, S., Carluccio, E., Bentivoglio, M., Buccolieri, M., Mariotti, M., Politano, M., & Corea, L. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00162-9 · Cited by 104
Homocysteine and Lipoprotein(a) Interact to Increase CAD Risk in Young Men and Women
Foody, J. M., MILBERG, J. A., Robinson, K., Pearce, G. L., Jacobsen, D. W., & Sprecher, D. L. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.2.493 · Cited by 103
Bostom, A. G., Selhub, J., Jacques, P. F., & Rosenberg, I. H. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00014 · Cited by 101
Pearson, T. A., Blair, S. N., Daniels, S. R., Eckel, R. H., Fair, J. M., Fortmann, S. P., Franklin, B. A., Goldstein, L. B., Greenland, P., Grundy, S. M., et al. (2002) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · Cited by 97
Cantin, B., Després, J., Lamarche, B., Moorjani, S., Lupien, P. J., Bogaty, P. M., Bergeron, J., & Dagenais, G. R. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02336-0 · Cited by 92
MacMahon, M., Kirkpatrick, C. A., Cummings, C. E., Clayton, A., Robinson, P. J., Tomiak, R. H. H., Liu, M., Kush, D., & Tobert, J. A. (2000) · PubMed · Cited by 91
Lipoprotein(a): from ancestral benefit to modern pathogen?
Lippi, G., & Guidi, G. (2000) · QJM · doi:10.1093/qjmed/93.2.75 · Cited by 90
Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells.
Levin, E. G., Miles, L. A., Fless, G. M., Scanu, A. M., Baynham, P. J., Curtiss, L. K., & Plow, E. F. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.3.438 · Cited by 80
Schnyder, G., Roffi, M., Flammer, Y., Pin, R., & Hess, O. M. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)01039-5 · Cited by 76
Lee, A. J., Fowkes, F. G. R., Lowe, G. D. O., Connor, J. M., & Rumley, A. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614523 · Cited by 73
Is High-Sensitivity C-Reactive Protein an Effective Screening Test for Cardiovascular Risk?
Kushner, I., & Sehgal, A. R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.8.867 · Cited by 73
Zwaka, T. P., Hombach, V., & Torzewski, J. (2001) · BMC News and views · doi:10.1186/2048-4623-1-s2-019 · Cited by 70
Tanné, D., Benderly, M., Goldbourt, U., Boyko, V., Brunner, D., Graff, E., Reicher-Reiss, H., Shotan, A., Mandelzweig, L., & Behar, S. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00914-7 · Cited by 61
Li, X.-N., Grenett, H. E., Benza, R. L., Demissie, S., Brown, S. L., Tabengwa, E. M., Gianturco, S. H., Bradley, W. A., Fless, G. M., & Booyse, F. M. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.11.3215 · Cited by 56
Therapeutic interventions to lower plasma fibrinogen concentration
Ernst, E., & Resch, K. L. (1995) · European Heart Journal · doi:10.1093/eurheartj/16.suppl_a.47 · Cited by 52
Mónica Acevedo, B., Pearce, G. L., Kottke‐Marchant, K., & Sprecher, D. L. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000020007.25154.62 · Cited by 47
Blake, G. J., Ridker, P. M., & Kuntz, K. M. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00074-3 · Cited by 44
Lowering blood homocysteine with folic acid-based supplements: meta-analysis of randomised trials.
Clarke, R. (2000) · PubMed · Cited by 44
Wilkes, H., Kelleher, C. C., & Meade, T. W. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90398-4 · Cited by 40
Solfrizzi, V., Panza, F., Colacicco, A. M., Capurso, C. A., D’Introno, A., Torres, F., Baldassarre, G., & Capurso, A. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02192-6 · Cited by 39
BCR/IFCC reference material for plasma proteins (CRM 470)
Whicher, J. T. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00035-6 · Cited by 38
Doshi, S. N., Moat, S. J., McDowell, I., LEWIS, M. J., & Goodfellow, J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00191-0 · Cited by 27
C-Reactive Protein in the Prediction of Cardiovascular Events
Evans, M. K., Zonderman, A. B., & Johnson, W. R. (2003) · New England Journal of Medicine · doi:10.1056/nejm200303133481115 · Cited by 25
C-reactive protein, inflammation and atherosclerosis: do we really understand it yet?
Weintraub, W. (2000) · European Heart Journal · doi:10.1053/euhj.2000.2109 · Cited by 24
Standardization and Clinical Management of Lipoprotein(a) Measurements
Lippi, G., & Guidi, G. C. (1998) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1998.003 · Cited by 16
Homocysteine: to screen and treat or to wait and see?
Genest, J. J., Audelin, M. C., & Lonn, E. (2000) · Europe PMC (PubMed Central) · Cited by 15
Wallis, E. J., Ramsay, L. E., Haq, I. U., Ghahramani, P., & Jackson, P. (2001) · Journal of Hypertension · doi:10.1097/00004872-200104000-00005 · Cited by 13
Homocysteine and cardiovascular disease: Current evidence and future prospects
Mangoni, A. A., & Jackson, S. H. D. (2002) · Research Portal (King's College London) · Cited by 7
Adjusting therapy to cardiovascular risk status
Pasternak, R. C. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00151-5 · Cited by 3
Cited by
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Vasan, R. S. (2006) · Circulation · doi:10.1161/circulationaha.104.482570 · Cited by 1,212
Inflammatory Markers and the Risk of Coronary Heart Disease in Men and Women
Pai, J. K., Pischon, T., Ma, J., Manson, J. E., Hankinson, S. E., Joshipura, K., Curhan, G. C., Rifai, N., Cannuscio, C. C., Stampfer, M. J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040967 · Cited by 1,174
Hlatky, M. A., Greenland, P., Arnett, D. K., Ballantyne, C. M., Criqui, M. H., Elkind, M. S. V., Go, A. S., Harrell, F. E., Hong, Y., Howard, B. V., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192278 · Cited by 1,139
Melamed, S., Shirom, A., Toker, S., Berliner, S., & Shapira, I. (2006) · Psychological Bulletin · doi:10.1037/0033-2909.132.3.327 · Cited by 943
Reactive oxygen species in cardiovascular disease
Sugamura, K., & Keaney (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.05.004 · Cited by 769
Metadata
- Authors
- Hackam, D. G., & Anand, S. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2003-08-20
- Volume
- 290
- Issue
- 7
- Pages
- 932
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2027086504
- Cited by
- 550
- References
- 126
- FWCI
- 49.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.